

# Sebastian Giebel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4706776/publications.pdf>

Version: 2024-02-01

182  
papers

6,059  
citations

87888

38  
h-index

95266

68  
g-index

188  
all docs

188  
docs citations

188  
times ranked

5895  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
2	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	1.2	13
3	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	2.4	9
4	The impact of blood donation on bone marrow harvest efficiency. <i>Bone Marrow Transplantation</i> , 2022, 57, 507-509.	2.4	0
5	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e14-e25.	4.6	27
6	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	7.0	12
7	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	2.4	4
8	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-eligible relapsed and refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
9	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
10	Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. <i>Cancer</i> , 2022, 128, 2922-2931.	4.1	17
11	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1591-1598.	3.5	29
12	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	2.4	36
13	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	32
14	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 171.e1-171.e8.	1.2	9
15	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 1190-1199.	2.4	16
16	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	2.4	2
17	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	2.4	10
18	High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1755-1767.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	7.2	6
20	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	4.6	26
21	Outcome of Tâ€cellâ€replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	4.1	8
22	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
23	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 53.	17.0	51
24	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	3.3	3
25	Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. <i>Cytotherapy</i> , 2021, 23, 483-487.	0.7	8
26	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	27.0	209
27	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). <i>Cancers</i> , 2021, 13, 4189.	3.7	6
28	Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1297-1304.	2.4	6
29	The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study. <i>Blood</i> , 2021, 138, 3453-3453.	1.4	0
30	Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2021, 138, 2876-2876.	1.4	1
31	Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). <i>Blood</i> , 2021, 138, 1787-1787.	1.4	1
32	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 595-602.	2.4	17
33	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 105-113.	0.4	3
34	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	7.2	48
35	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	1.3	1
36	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Blinatumomab vs historic standard of care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	2.2	17
38	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. <i>Frontiers in Immunology</i> , 2020, 11, 1537.	4.8	2
39	Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Dermatology and Therapy</i> , 2020, 10, 1043-1061.	3.0	2
40	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia &gt;45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1560-1569.	2.4	16
41	Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1833-1839.	2.0	14
42	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	17.0	44
43	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP—the PLRG report. <i>Scientific Reports</i> , 2020, 10, 3517.	3.3	12
44	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
45	Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. <i>Frontiers in Immunology</i> , 2020, 10, 3097.	4.8	14
46	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1763-1772.	2.4	14
47	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. <i>Transplantation Proceedings</i> , 2020, 52, 2178-2185.	0.6	12
48	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
49	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
50	Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2551-2553.	0.6	1
51	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	7.2	30
52	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
53	Clinical manifestations of diffuse large B-cell lymphoma in the skin and subcutaneous tissue a case series study. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 812-816.	0.9	2
54	Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures. <i>Advances in Clinical and Experimental Medicine</i> , 2020, 29, 1221-1230.	1.4	6

#	ARTICLE	IF	CITATIONS
55	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
56	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
57	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients $\geq$ 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0
58	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 40-42.	1.4	0
59	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	2.4	54
60	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Annals of Hematology</i> , 2019, 98, 2389-2398.	1.8	24
61	Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. <i>Annals of Hematology</i> , 2019, 98, 2197-2211.	1.8	25
62	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	17.0	51
63	Multi-institutional evaluation of MVCT guided patient registration and dosimetric precision in total marrow irradiation: A global health initiative by the international consortium of total marrow irradiation. <i>Radiotherapy and Oncology</i> , 2019, 141, 275-282.	0.6	14
64	Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 264-274.e4.	0.4	9
65	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 186, 767-776.	2.5	31
66	Hodgkin lymphoma transformation of chronic lymphocytic leukemia—A real life data from the Polish Lymphoma Research Group. <i>Hematological Oncology</i> , 2019, 37, 383-391.	1.7	3
67	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	1.5	48
68	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2019, 106, 212-219.	2.8	13
69	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia — a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
70	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
71	Dermoscopic follow-up of therapeutic response in mantle cell lymphoma with secondary involvement of the scalp. <i>Journal of Cosmetic Dermatology</i> , 2019, 18, 1438-1440.	1.6	3
72	Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 248-255.	2.0	14



#	ARTICLE	IF	CITATIONS
73	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Hematology International</i> , 2019, 1, 19.	1.7	15
74	Stosowanie lekã³w biopodobnych w hematoonkologii â€“ stanowisko Polskiego Towarzystwa Hematologã³w i Transfuzjologã³w. <i>Acta Haematologica Polonica</i> , 2019, 50, 51-56.	0.3	0
75	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 43-43.	1.4	0
76	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	2.4	23
77	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	2.8	40
78	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	4.1	21
79	Antiâ€thymocyte globulin improves survival free from relapse and graftâ€versusâ€host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphiaâ€negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the <scp>EBMT</scp>. <i>Cancer</i> , 2018, 124, 2523-2533.	4.1	18
80	Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2018, 53, 274-280.	2.4	39
81	HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. <i>Human Immunology</i> , 2018, 79, 403-412.	2.4	9
82	What is the outcome in patients with acute leukaemia who survive severe acute graftâ€versusâ€host disease?. <i>Journal of Internal Medicine</i> , 2018, 283, 166-177.	6.0	10
83	Evaluation of proinflammatory and immunosuppressive cytokines in blood and bone marrow of healthy hematopoietic stem cell donors. <i>Cytokine</i> , 2018, 102, 181-186.	3.2	9
84	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 515-526.	0.8	25
85	The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). <i>Frontiers in Immunology</i> , 2018, 9, 2153.	4.8	15
86	Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. <i>Wspolczesna Onkologia</i> , 2018, 22, 113-117.	1.4	5
87	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	5.2	34
88	Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 39-46.	0.9	2
89	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
90	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.3	4

#	ARTICLE	IF	CITATIONS
91	Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG). <i>Acta Haematologica Polonica</i> , 2018, 49, 234-239.	0.3	1
92	Stanowisko polskich ekspertów dotyczący zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skłony CD30+. <i>Hematologia</i> , 2018, 9, 83-89.	0.0	0
93	Szczepienia ochronne u dorosłych chorych na nowotwory hematologiczne oraz u chorych z asplenią... zalecenia PTHiT i sekcji do spraw zakażeń, PALG. <i>Acta Haematologica Polonica</i> , 2018, 49, 93-101.	0.3	5
94	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	4.1	24
95	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	4.1	31
96	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	4.1	17
97	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	4.1	34
98	Szczepienia ochronne u chorych dorosłych po przeszczepieniu komórek krwiotwórczych zalecenia sekcji do spraw zakażeń, PALG. <i>Acta Haematologica Polonica</i> , 2017, 48, 1-9.	0.3	9
99	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 139-149.	3.5	88
100	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	3.5	108
101	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	3.5	64
102	Zalecenia Polskiej Grupy Szpiczakowej dotyczący rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017, 48, 55-103.	0.3	5
103	Rytuksymab – pierwsze biopodobne przeciwciała monoklonalne w hematologii. <i>Acta Haematologica Polonica</i> , 2017, 48, 269-273.	0.3	1
104	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 113.	17.0	60
105	Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. <i>Journal of Clinical Apheresis</i> , 2017, 32, 295-301.	1.3	8
106	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia – A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	4.1	11
107	First Complex Allotransplantation of Neck Organs. <i>Annals of Surgery</i> , 2017, 266, e19-e24.	4.2	25
108	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	5.2	151

#	ARTICLE	IF	CITATIONS
109	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017, 8, 112972-112979.	1.8	22
110	Dermoscopic Follow-Up of the Skin towards Acute Graft-versus-Host-Disease in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>BioMed Research International</i> , 2016, 2016, 1-6.	1.9	9
111	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
112	The First Immediate Face Transplant in the World. <i>Annals of Surgery</i> , 2016, 263, e36-e39.	4.2	52
113	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	3.5	42
114	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 2941-2951.	4.1	140
115	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	4.1	31
116	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	3.5	154
117	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	3.5	35
118	Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 834-842.	2.0	16
119	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. <i>Oncologist</i> , 2016, 21, 377-383.	3.7	10
120	Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 679-687.	0.8	14
121	Immunological properties of bone marrow microenvironment 1 year after allogeneic hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2016, 44, 1172-1180.e1.	0.4	3
122	Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. <i>Blood</i> , 2016, 127, 360-362.	1.4	34
123	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.3	10
124	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 25.	17.0	57
125	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 1431-1438.	2.4	161
126	Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. <i>Annals of Hematology</i> , 2016, 95, 263-269.	1.8	9



#	ARTICLE	IF	CITATIONS
127	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 351-357.	2.4	68
128	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	1.4	1
129	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , 2016, 11, e0150637.	2.5	28
130	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	2.5	26
131	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	1.4	93
132	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (alloâ€œHSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study. <i>American Journal of Hematology</i> , 2015, 90, 904-909.	4.1	4
133	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk groupâ€œan observational analysis by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2015, 50, 1063-1068.	2.4	41
134	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. <i>Acta Haematologica Polonica</i> , 2015, 46, 49-55.	0.3	0
135	Follow-up of patients with mycosis fungoides after interferon Î±2b treatment failure. <i>Postepy Dermatologii i Alergologii</i> , 2015, 2, 67-72.	0.9	6
136	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3144-3151.	1.6	119
137	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2331-2338.	1.3	9
138	Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. <i>Medical Oncology</i> , 2015, 32, 90.	2.5	8
139	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.3	0
140	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. <i>Bone Marrow Transplantation</i> , 2015, 50, 1495-1502.	2.4	44
141	Dermoscopy in near-full facial transplantation. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, S19-S21.	1.2	8
142	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncologist</i> , 2015, 20, 50-55.	3.7	9
143	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2015, 126, 863-863.	1.4	23
144	PostÄ™py w przeszczepianiu krwiotwÃ³rczych komÃ³rek macierzystych. <i>Hematologia</i> , 2015, 6, 85-89.	0.0	1

#	ARTICLE	IF	CITATIONS
145	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 4316-4316.	1.4	0
146	Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2014, 120, 2760-2765.	4.1	73
147	Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Cancer</i> , 2014, 50, 411-417.	2.8	60
148	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. <i>Human Immunology</i> , 2014, 75, 508-513.	2.4	8
149	Injection of G-CSF During Leukaphereses Reduces the Number of Aphereses Needed for Mobilization in Unrelated Hematopoietic Stem Cell Donors. <i>Annals of Transplantation</i> , 2014, 19, 444-446.	0.9	1
150	Napromienianie szpiku caÅ,ego ciaÅ,a â€” prezentacja metody. <i>Nowotwory</i> , 2014, 64, 314-320.	0.3	1
151	A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. <i>Cryobiology</i> , 2013, 67, 327-331.	0.7	31
152	Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B cell lymphoma. <i>European Journal of Haematology</i> , 2013, 91, 122-128.	2.2	28
153	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 238-242.	2.4	25
154	Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2441-2448.	1.6	214
155	The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. <i>European Journal of Cancer</i> , 2012, 48, 360-367.	2.8	15
156	Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells. <i>International Journal of Hematology</i> , 2012, 96, 287-289.	1.6	9
157	Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. <i>European Journal of Haematology</i> , 2011, 86, 488-495.	2.2	34
158	Association of KIR2DS4 gene with susceptibility to leukemia: Chineseâ€”Polish discrepancy. <i>Leukemia Research</i> , 2011, 35, 1540.	0.8	0
159	The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study. <i>American Journal of Hematology</i> , 2011, 86, 437-439.	4.1	12
160	Plerixafor to rescue failing chemotherapy-based stem cell mobilization: itâ€™s not too late. <i>Leukemia and Lymphoma</i> , 2011, 52, 1711-1719.	1.3	22
161	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. <i>Haematologica</i> , 2011, 96, 1344-1350.	3.5	67
162	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. <i>Blood</i> , 2010, 116, 122-128.	1.4	36

#	ARTICLE	IF	CITATIONS
163	Does the KIR2DS5 Gene Protect from Some Human Diseases?. PLoS ONE, 2010, 5, e12381.	2.5	45
164	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. Journal of Clinical Oncology, 2010, 28, 3344-3351.	1.6	83
165	Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 1022-1030.	2.4	25
166	Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). International Journal of Infectious Diseases, 2010, 14, e132-e140.	3.3	33
167	Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance. Blood, 2010, 116, 172-172.	1.4	15
168	Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2009, 83, 343-356.	2.2	38
169	Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Annals of Hematology, 2009, 88, 1005-1013.	1.8	20
170	Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Philadelphia-negative acute lymphoblastic leukaemia?. British Journal of Haematology, 2009, 144, 970-972.	2.5	2
171	Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of The Polish Acute Leukemia Group. Leukemia and Lymphoma, 2009, 50, 478-480.	1.3	2
172	Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. Leukemia and Lymphoma, 2009, 50, 1050-1053.	1.3	2
173	Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-CM) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. European Journal of Haematology, 2008, 80, 115-126.	2.2	122
174	Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British Journal of Haematology, 2008, 142, 284-292.	2.5	24
175	Status of minimal residual disease after induction predicts outcome in both standard and high-risk Philadelphia-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. British Journal of Haematology, 2008, 142, 227-237.	2.5	134
176	Serum Leptin and Ghrelin Levels in Premenopausal Women with Stable Body Mass Index during Treatment of Thyroid Dysfunction. Thyroid, 2008, 18, 545-550.	4.5	22
177	Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Annals of Hematology, 2006, 85, 717-722.	1.8	23
178	Low percentages of circulating CD8+/CD45RA+ human T lymphocytes expressing Î²7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2006, 34, 1429-1434.	0.4	4
179	Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology, 2005, 131, 483-486.	2.5	31
180	B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Experimental Hematology, 2005, 33, 480-486.	0.4	74

#	ARTICLE	IF	CITATIONS
181	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. <i>Blood</i> , 2003, 102, 814-819.	1.4	515
182	G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 315-325.	1.3	31